Literature DB >> 12525988

[Sonographical breast biopsy: how many core biopsy specimens are needed?].

R Schulz-Wendtland1, U Aichinger, S Krämer, M Tartsch, I Kuchar, A Magener, W Bautz.   

Abstract

PURPOSE: To determine the optimum number of specimens of a sonographically guided core biopsy of the breast.
MATERIALS AND METHODS: From January 2001 to April 2001, sonographically guided core biopsies (coaxial needle: 11 G; core needle: 12 G) were performed on 106 patients with 115 BI-RADS trade mark 4-5 lesions that had corresponding sonographic findings. Five specimens were obtained in anteroposterior direction parallel to the chest wall and each specimen examined histologically.
RESULTS: A total of 575 core biopsies produced 545 specimens (94.8 %), with no material obtained in 30 biopsies (5.2 %). The first and second specimen confirmed the diagnosis in 99 of 115 lesions (86 %), with subsequent specimens confirming the diagnosis in 87 % (3 rd specimen), 88 % (4 th specimen) and 82 % (5 th specimen). The additive accuracy of the five core breast specimens was 86 %, 96 %, 98 %, 99 % and 100 %. The possible volume of 78.9 mm 3 as determined by the sample notch of the core needle only furnished an average volume of 38.1 mm 3 (41.1 mm 3 for the 1 st, 40.1 mm 3 for the 2 nd, 37.5 mm 3 for the 3 rd, 36.7 mm 3 for the 4 th and 35.0 mm 3 for 5 th core specimen).
CONCLUSION: Sonographically guided core breast biopsy (coaxial needle: 11 G; core needle: 12 G) may require five passes to achieve a diagnostic accuracy of more than 99 %.

Entities:  

Mesh:

Year:  2003        PMID: 12525988     DOI: 10.1055/s-2003-36599

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  2 in total

1.  [Percutaneous large core breast biopsy].

Authors:  K Prechtel; J de Waal; A Nerlich; D Hölzel; J Weitz
Journal:  Pathologe       Date:  2006-05       Impact factor: 1.011

2.  Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer.

Authors:  Achim Wöckel; Jasmin Festl; Tanja Stüber; Katharina Brust; Stephanie Stangl; Peter U Heuschmann; Ute-Susann Albert; Wilfried Budach; Markus Follmann; Wolfgang Janni; Ina Kopp; Rolf Kreienberg; Thorsten Kühn; Thomas Langer; Monika Nothacker; Anton Scharl; Ingrid Schreer; Hartmut Link; Jutta Engel; Tanja Fehm; Joachim Weis; Anja Welt; Anke Steckelberg; Petra Feyer; Klaus König; Andrea Hahne; Hans H Kreipe; Wolfram Trudo Knoefel; Michael Denkinger; Sara Brucker; Diana Lüftner; Christian Kubisch; Christina Gerlach; Annette Lebeau; Friederike Siedentopf; Cordula Petersen; Hans Helge Bartsch; Rüdiger Schulz-Wendtland; Markus Hahn; Volker Hanf; Markus Müller-Schimpfle; Ulla Henscher; Renza Roncarati; Alexander Katalinic; Christoph Heitmann; Christoph Honegger; Kerstin Paradies; Vesna Bjelic-Radisic; Friedrich Degenhardt; Frederik Wenz; Oliver Rick; Dieter Hölzel; Matthias Zaiss; Gudrun Kemper; Volker Budach; Carsten Denkert; Bernd Gerber; Hans Tesch; Susanne Hirsmüller; Hans-Peter Sinn; Jürgen Dunst; Karsten Münstedt; Ulrich Bick; Eva Fallenberg; Reina Tholen; Roswita Hung; Freerk Baumann; Matthias W Beckmann; Jens Blohmer; Peter A Fasching; Michael P Lux; Nadia Harbeck; Peyman Hadji; Hans Hauner; Sylvia Heywang-Köbrunner; Jens Huober; Jutta Hübner; Christian Jackisch; Sibylle Loibl; Hans-Jürgen Lück; Gunter von Minckwitz; Volker Möbus; Volkmar Müller; Ute Nöthlings; Marcus Schmidt; Rita Schmutzler; Andreas Schneeweiss; Florian Schütz; Elmar Stickeler; Christoph Thomssen; Michael Untch; Simone Wesselmann; Arno Bücker; Mathias Krockenberger
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-10-19       Impact factor: 2.915

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.